128 related articles for article (PubMed ID: 21786247)
1. Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis.
Yang K; Chen XZ; Zhang B; Yang C; Chen HN; Chen ZX; Zhou ZG; Chen JP; Hu JK
Int J Biol Markers; 2011; 26(3):173-80. PubMed ID: 21786247
[TBL] [Abstract][Full Text] [Related]
2. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
3. A distinct subpopulation within CD133 positive brain tumor cells shares characteristics with endothelial progenitor cells.
Choi SA; Wang KC; Phi JH; Lee JY; Park CK; Park SH; Kim SK
Cancer Lett; 2012 Nov; 324(2):221-30. PubMed ID: 22652175
[TBL] [Abstract][Full Text] [Related]
4. [Preliminary interpretation on the relationship between the phenotype of CD133+ cells and niche in transplanted human glioma in mice].
Song WC; Fei XF; Dong J
Zhonghua Zhong Liu Za Zhi; 2010 Aug; 32(8):564-9. PubMed ID: 21122405
[TBL] [Abstract][Full Text] [Related]
5. In vivo investigation of CD133 as a putative marker of cancer stem cells in Hep-2 cell line.
Wei XD; Zhou L; Cheng L; Tian J; Jiang JJ; Maccallum J
Head Neck; 2009 Jan; 31(1):94-101. PubMed ID: 18853445
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
7. Cell cycle analysis of the CD133(+) and CD133(-) cells isolated from human colorectal cancer.
Gharagozloo M; Mirzaei HR; Bagherpour B; Rezaei A; Kalantari H; Sanei MH; Hosseini M; Mohajeri G; Tabatabai A; Hashemi M
J Cancer Res Ther; 2012; 8(3):399-403. PubMed ID: 23174722
[TBL] [Abstract][Full Text] [Related]
8. CD133 is essential for glioblastoma stem cell maintenance.
Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
[TBL] [Abstract][Full Text] [Related]
9. Effects of heterochromatin in colorectal cancer stem cells on radiosensitivity.
Chen T; Zhang Y; Guo WH; Meng MB; Mo XM; Lu Y
Chin J Cancer; 2010 Mar; 29(3):270-6. PubMed ID: 20193109
[TBL] [Abstract][Full Text] [Related]
10. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
11. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
12. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.
Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R
Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas.
Joo KM; Kim SY; Jin X; Song SY; Kong DS; Lee JI; Jeon JW; Kim MH; Kang BG; Jung Y; Jin J; Hong SC; Park WY; Lee DS; Kim H; Nam DH
Lab Invest; 2008 Aug; 88(8):808-15. PubMed ID: 18560366
[TBL] [Abstract][Full Text] [Related]
14. CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.
Hongo K; Tanaka J; Tsuno NH; Kawai K; Nishikawa T; Shuno Y; Sasaki K; Kaneko M; Hiyoshi M; Sunami E; Kitayama J; Takahashi K; Nagawa H
J Surg Res; 2012 Jun; 175(2):278-88. PubMed ID: 21601882
[TBL] [Abstract][Full Text] [Related]
15. CD133 as a marker for cancer stem cells: progresses and concerns.
Wu Y; Wu PY
Stem Cells Dev; 2009 Oct; 18(8):1127-34. PubMed ID: 19409053
[TBL] [Abstract][Full Text] [Related]
16. Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis.
Pallini R; Ricci-Vitiani L; Montano N; Mollinari C; Biffoni M; Cenci T; Pierconti F; Martini M; De Maria R; Larocca LM
Cancer; 2011 Jan; 117(1):162-74. PubMed ID: 20806346
[TBL] [Abstract][Full Text] [Related]
17. CD133 expression and the prognosis of colorectal cancer: a systematic review and meta-analysis.
Chen S; Song X; Chen Z; Li X; Li M; Liu H; Li J
PLoS One; 2013; 8(2):e56380. PubMed ID: 23409180
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the Ras-Raf Axis underlie the prognostic value of CD133 in colorectal cancer.
Kemper K; Versloot M; Cameron K; Colak S; de Sousa e Melo F; de Jong JH; Bleackley J; Vermeulen L; Versteeg R; Koster J; Medema JP
Clin Cancer Res; 2012 Jun; 18(11):3132-41. PubMed ID: 22496204
[TBL] [Abstract][Full Text] [Related]
19. Co-expression of stem cell genes CD133 and CD44 in colorectal cancers with early liver metastasis.
Huang X; Sheng Y; Guan M
Surg Oncol; 2012 Jun; 21(2):103-7. PubMed ID: 21764578
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]